ClinicalTrials.gg
TerminatedNCT05417477RHUMATO-APPUpdated Nov 10, 2026

Evaluation of a Connected Interface to Improve the Quality of Life and the Disability of Patient With Rheumatic Diseases

An interventional study of use of an e-health application in Rheumatoid Arthritis, sponsored by University Hospital, Montpellier. Terminated at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Problems encountered with the device used in the study
Updated Nov 10, 2026Now TerminatedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier — 6 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · University Hospital, Montpellier.

Enrollment
12th of 15
29 · median 87
Started
2024
the only one that year
No phase
13 of 27
2 open now
Registered
22nd of 27
by date

Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 22nd registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

6 of the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, or all of them as a file.
02

Study summary

Musculoskeletal pathologies constitute a major public health problem. Rheumatologists, whether they practice in private or hospital settings, play a major role in the management of responsible for these ailments.

Due to the increase in life expectancy, an increase in the number of consultations can be expected. It is therefore imperative that the latter be more efficient, without losing quality.

Communication between doctor and patient is bound to evolve due to the multiplicity of IT tools available and those that are emerging, which are increasingly essential, including many smartphone applications. Each targeting a specific pathology (rheumatoid arthritis, ankylosing spondylitis, osteoporosis osteoarthritis, they will allow the patient to self-assess, thus becoming an actor in his own care.

A "facilitated" exchange between caregivers and patients would be relevant and would provide added value for all. This is the reason why there is a real need for an application listing precise information on the patient, in a sufficiently succinct way to optimize their transmission to the physiotherapist.

Read the detailed description

Musculoskeletal pathologies constitute a major public health problem. Rheumatologists, whether they practice in private or hospital settings, play a major role in the management of responsible for these ailments.

Due to the increase in life expectancy, an increase in the number of consultations can be expected. It is therefore imperative that the latter be more efficient, without losing quality.

Communication between doctor and patient is bound to evolve due to the multiplicity of IT tools available and those that are emerging, which are increasingly essential, including many smartphone applications. Each targeting a specific pathology (rheumatoid arthritis, ankylosing spondylitis, osteoporosis osteoarthritis, they will allow the patient to self-assess, thus becoming an actor in his own care.

A "facilitated" exchange between caregivers and patients would be relevant and would provide added value for all. This is the reason why there is a real need for an application listing precise information on the patient, in a sufficiently succinct way to optimize their transmission to the physiotherapist.

Our team has recently highlighted that monitoring rheumatoid arthritis in connected mode (smartphone + online interface for the physician + distancing interaction patient / caregiver) provided a benefit in terms of quality of life as well as on the medico-economics level compared to conventional monitoring, without affecting the control of rheumatoid arthritis activity. Telemedicine is positioned more than ever as an essential instrument for organizing the longitudinal monitoring of diseases, especially in a context of confinement, which implies limited access to physiotherapy sessions, even though these are essential for optimizing the management of many osteoarticular disorders. By promoting the use of a digital telemedicine tool in the follow-up of patients suffering from rheumatological pathologies in both private practice and hospitals, the Rhumato-App project aims to develop an ergonomic offline/online platform for patients/healthcare providers (e.g. rheumatologist, general practitioner, physiotherapist), accessible from a computer or a smartphone. This platform will improve the articulation of the patient's care pathway by feeding a secure medical file shared between caregivers.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatic and musculoskeletal diseases
  • e-health
  • care pathway
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 70 years
  • Presence of a chronic inflammatory rheumatism (rheumatoid arthritis, axial and/or peripheral spondyloarthritis) or osteoarthritis disease requiring the initiation of at least 20 sessions of physical therapy
  • Diagnostic confirmation left to the discretion of the investigating physician
  • Accessibility of an internet network (compatible with smartphone and/or computer)
  • Information and consent of the patient

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Patient refusing or unable to give consent: patient under guardianship or curator, mentally retarded, dementia, language barrier
  • Patient not affiliated to a social security scheme
  • Patient under legal protection
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    chronic inflammatory rheumatism or osteoarthritis

    The experimental intervention consists in providing the patient with access to a specific version of the application ''MedicApp'' for the duration of the study. The intervention will be limited for each patient to the entry of their data on the application at regular intervals during the study. The interface on the rheumatologist side will contain the demographic characteristics of the patient, his history, the treatments and the pathology requiring the use of physiotherapy Then, at regular intervals, the scores of the questionnaires addressed to the patient will be available on his interface. The interface, on the physiotherapist side, will contain the summary of the patient's clinical history, his treatments and the reason for the physiotherapy sessions. Then, at regular intervals, the physiotherapist will indicate the patient's locomotor assessment, the type of intervention performed and the final summary.

    Device: use of an e-health application

Interventions

  • Deviceuse of an e-health application

    Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.

06

What researchers measure

Primary outcomes

  1. Change of the quality of life of patients between baseline and 6 months

    Evaluate the impact of the computer interface on the patient's quality of life by comparing the evolution of the global SF-12 score between baseline and 6 months (longitudinal follow-up). The Survey Form-12 (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life. The SF-12 is a shortened version of SF-36. The SF-12 have eight domains : 1. Limitations in physical activities because of health problems. 2. Limitations in social activities because of physical or emotional problems 3. Limitations in usual role activities because of physical health problems 4. Bodily pain 5. General mental health (psychological distress and well-being) 6. Limitations in usual role activities because of emotional problems 7. Vitality (energy and fatigue) 8. General health perceptions

    Time frame: between baseline and 6 months

Secondary outcomes

  1. Percentage of satisfied patients

    To assess the patient's satisfaction with the use of this device at the end of the 6-month follow-up with the F-SUS (French System Usability Scale) questionnaire. The F-SUS (French System Usability Scale) is a 10-items, to determine the level of satisfaction of users of a service and the usability of the interactive system of the study. Score range from 1 to 5 with 1=totally disagree and 5=totally agree

    Time frame: between inclusion and 6 months

  2. Percentage of patients adhering to the interface

    Evaluate the patient's adherence to the use of a computer interface based on the weekly filling rate during the 6-month follow-up

    Time frame: between baseline and 6 months

  3. Percentage of adherent patients whose disease activity is positively impacted

    Assess the association between patient adherence and change in disease activity level between baseline and 6 months

    Time frame: between baseline and 6 months

  4. Percentage of adherent patients whose quality of life is positively impacted

    Evaluate the association between patient compliance and the variation in their quality of life between baseline and 6 months

    Time frame: between baseline and 6 months

  5. Percentage of adherent patients who are satisfied with the intervention

    Assess the association between patient adherence and satisfaction at 6 months

    Time frame: between baseline and 6 months

  6. Percentage of satisfied caregivers

    Assess the satisfaction of caregivers (physiotherapist, rheumatologist) with the use of this device at the end of the 6-month follow-up

    Time frame: between baseline and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Mar 2025, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Oct 2023 → May 2024, primary completion Dec 2023 → Mar 2025 and completion Dec 2023 → Mar 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 14, 2022
StartActual
May 23, 2024was Oct 2023
Primary completionActual
Mar 31, 2025was Dec 2023
CompletionActual
Mar 31, 2025was Dec 2023
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated Problems encountered with the device used in the study
changed Nov 10, 2026
Sites
1 site added, 1 site removed
Show site
  • Centre Hospitalier Universitaire de Montpellier · Montpellier, France
Show 1 removed
  • Centre Hospitalier Universitaire de Montpellier · Montpellier, France
Nov 10, 2026
Start date
Oct 1, 2023→May 23, 2024 (actual)
Nov 10, 2026
Primary completion
Dec 22, 2023→Mar 31, 2025 (actual)
Nov 10, 2026
Study completion
Dec 22, 2023→Mar 31, 2025 (actual)
Nov 10, 2026
Enrollment
80 (estimated)→29 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Terminated
    Why stopped Problems encountered with the device used in the study
    1 site added, 1 site removed
    Show site
    • Centre Hospitalier Universitaire de Montpellier · Montpellier, France
    Show 1 removed
    • Centre Hospitalier Universitaire de Montpellier · Montpellier, France
    Start date Oct 1, 2023→May 23, 2024 (now actual)
    Primary completion Dec 22, 2023→Mar 31, 2025 (now actual)
    Study completion Dec 22, 2023→Mar 31, 2025 (now actual)
    Enrollment 80 (estimated)→29 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05417477
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
May 23, 2024
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion